Literature DB >> 12707576

Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?

Yolanda Braun-Moscovici1, Daniel E Furst.   

Abstract

There is no simple answer to the question: intravenous immunoglobulin-take it or leave it? A thorough review of the current data on mechanisms of action, efficacy, and safety of intravenous immunoglobulins in rheumatic diseases demonstrates that the answer depends on the disease and the patients involved.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12707576     DOI： 10.1097/00002281-200305000-00010

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN： 1040-8711            Impact factor:   5.006


  9 in total

Review 1.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 5.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

Review 6.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 7.  Indications for IVIG in rheumatic diseases.

Authors:  Ben Mulhearn; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

Review 8.  Cells of the synovium in rheumatoid arthritis. B cells.

Authors:  Claudia Mauri; Michael R Ehrenstein
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 9.  The Production Processes and Biological Effects of Intravenous Immunoglobulin.

Authors:  Ana Filipa Barahona Afonso; Cristina Maria Pires João
Journal:  Biomolecules       Date:  2016-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.